Core Viewpoint - Medtronic has agreed to acquire Scientia Vascular for $550 million to enhance its product offerings in stroke care [1] Group 1: Acquisition Details - The acquisition is valued at $550 million and aims to expand Medtronic's product line in stroke care [1] - Scientia Vascular, based in Salt Lake City, employs approximately 310 people and specializes in guidewires and catheters for navigating brain blood vessels [1] - The integration of Scientia's products into Medtronic's existing neurovascular suite is expected to enhance support for both hemorrhagic and acute ischemic stroke procedures [1] Group 2: Financial Expectations - Medtronic anticipates the deal will close in the first half of fiscal 2027 [1] - The company expects the acquisition to be minimally dilutive to its adjusted earnings in 2027 and accretive thereafter [1] - Potential earn-out and milestone payments may be included post-acquisition, although specific details were not disclosed [1]

Core Insights - Medtronic has entered into a definitive agreement to acquire Scientia Vascular for $550 million, enhancing its neurovascular portfolio with innovative access technologies [1][1][1] - The acquisition aims to improve procedural efficiency in neurovascular care, addressing challenges in stroke treatment where timely intervention is critical [1][1][1] Company Overview - Scientia Vascular, based in Salt Lake City, Utah, employs approximately 310 people and specializes in access products for complex neurovascular conditions [1][1] - Medtronic's Neurovascular business is part of its broader Neuroscience Portfolio, focusing on eliminating the burden of stroke and other neurovascular diseases globally [1][1] Product Integration - Scientia's guidewires and catheters will be integrated with Medtronic's existing neurovascular products, enhancing the procedural workflow for physicians [1][1] - The acquisition is expected to provide a comprehensive portfolio that supports both hemorrhagic and acute ischemic stroke procedures [1][1] Market Impact - Stroke is the third leading cause of death and the leading cause of disability worldwide, with 12 million people affected annually [1][1] - The acquisition is anticipated to be minimally dilutive to Medtronic's adjusted EPS in FY27 and accretive thereafter, indicating a positive financial outlook post-acquisition [1][1]